|Achieving Long-Term Treatment for Severe Autoimmune Diseases with Neovacs’ Kinoid Polyclonal Antibody Active Immunotherapy|
|By Guy-Charles Fanneau de La Horie, CEO of Neovacs S.A.|
|Tuesday, 01 March 2011 03:11|
As a result, there remain significant unmet medical needs in these autoimmune diseases, which affect millions of Americans and tens of millions of people worldwide. To address these challenges, French biotechnology company Neovacs S.A. (Alternext Paris: ALNEV) has developed a novel active immunotherapy platform, the Kinoid, that uses the body’s own immune system to produce polyclonal antibodies to suppress disease-causing cytokine over-production. As well as the potential advantages of broader and longer-lasting efficacy, Neovacs Kinoid therapy provides a more convenient dosing regimen than mAbs, with only 3 – 4 injections per year, at potentially much lower cost than mAbs, which typically cost $15,000 to $20,000 per patient each year.
In a Phase I/II clinical trial of TNF- Kinoid in patients with Crohn’s Disease, Neovacs found the active immunotherapy had an excellent safety profile in all subjects and induced the production of anti-TNF (tumor necrosis factor) antibodies in 80 percent of patients.
The Crohn’s disease trial patients also had a high sustained clinical response rate at 20 weeks, i.e. 4 months after the last injection with 72% showing clinical improvement and nearly half (44%) in clinical remission. An analysis of calprotectin, a biomarker for intestinal inflammation, showed a normal calprotectin level in 7 of 10 patients at 12 weeks, a sharp decline over baseline, indicating reduced inflammation of the intestinal mucosa. Further, mucosal healing was observed in 6 patients out of 9 who received endoscopies.
Neovacs is now conducting two Phase II clinical trials in Europe, one in rheumatoid arthritis patients who have failed at least one TNF inhibitor, and the second in Crohn’s patients, also having failed a TNF inhibitor.
To address the limitations of current monoclonal antibody therapies for severe autoimmune diseases, Neovacs is developing Kinoid polyclonal antibody active immunotherapy to safely, affordably and effectively provide long-term treatment for rheumatoid arthritis and Crohn’s disease with TNF-Kinoid and IFNα-Kinoid for lupus.
Author Guy-Charles Fanneau de La Horie is the Chief Executive Officer of Neovacs S.A. in Paris, France.
He contributed this expert briefing for our readers.